Trending Now
Drug Discovery and Development
First FDA breakthrough therapy designation in PSMA PET imaging granted to Cu-64 SAR-bisPSMA in biochemical recurrence of prostate cancer
The United States Food and Drug Administration (FDA) has granted Clarity Pharmaceuticals’ 64Cu-SAR-bisPSMA breakthrough therapy designation for positron emission tomography (PET) of prostate-specific membrane...
FDA authorises Lynch Regenerative Medicine’s IND for a phase 2b clinical trial for injection of rhPDGF-BB for treatment of infraorbital hollowing
An Investigational New Drug (IND) application for Lynch Regenerative Medicine's phase 2 clinical trial evaluating injectable recombinant human platelet-derived growth factor-BB (rhPDGF-BB) in adults...
Rznomics granted orphan medicinal product designation for RZ-001 for the treatment of glioma by the European Commission
Rznomics Inc, a biopharmaceutical company specialising in the development of RNA-based gene therapies, announced that the European Commission (EC) has granted orphan medicinal product...
European Medicines Agency grants ‘prime’ designation to Calico Life Sciences’ investigational fosigotifator for vanishing white matter
Calico Life Sciences, a clinical-stage biotechnology organisation focused on aging and age-related diseases and founded by Alphabet and Arthur D Levinson, has announced that...
Harbour BioMed receives China NMPA approval of batoclimab injection (subcutaneous injection) for the treatment of generalised myasthenia gravis
The National Medical Products Administration (NMPA) of China has approved the Biologics License Application (BLA) for Harbour BioMed’s batoclimab injection (subcutaneous injection) (batoclimab SC),...
Adalvo expands biosimilars portfolio through acquisition of romiplostim biosimilar programme from Enzene
Adalvo has acquired the romiplostim biosimilar programme referencing Nplate from Enzene, strengthening its biosimilars portfolio and accelerating the company’s expansion into complex biological medicines.
The...
Lilly breaks ground in Richmond to expand American manufacturing of next-generation cancer medicines, advancing its build-out of 10 new US sites since 2020
Eli Lilly and Company has broken ground on a new $5 billion manufacturing facility just west of Richmond, Virginia, USA – one of 10...
Takara Bio USA partners with SPT Labtech to deliver automation-ready NGS library preparation technologies
Takara Bio USA and SPT Labtech have partnered to deliver validated, automated library preparation workflows that combine Takara Bio next-generation sequencing (NGS) library preparation...
Leads Biolabs’ bispecific antibody pamtistomig granted FDA fast track designation for first-line advanced or metastatic biliary tract cancer
The US Food and Drug Administration (FDA) has granted fast track designation to Nanjing Leads Biolabs core product opamtistomig (LBL-024), a PD-L1/4-1BB bispecific antibody,...
Xylyx Bio announces FDA orphan drug designation and US $2.99m grant award for its lead organ graft product, Inspirex Lung
The US Food and Drug Administration (FDA) has granted Orphan Drug Designation to Inspirex Lung, Xylyx Bio's lead investigational candidate for the treatment of...
Aro Biotherapeutics reports therapeutic potential of Centyrin – IFIH1 siRNA conjugate for the treatment of type 1 diabetes
Aro Biotherapeutics, a clinical-stage biotechnology company developing potent and tissue-targeted short-interfering RNA (siRNA) medicines, has announced preclinical data highlighting the therapeutic potential of its proprietary...
UCB dedicates site for new US biologics manufacturing campus in Georgia
UCB has announced the future site of its new US biologics manufacturing campus at Rowen in Gwinnett County, Georgia.
The ceremony brought together Georgia, US...
T-Maximum’s targeted allogeneic CAR-T MT027 receives FDA clearance for phase 2 study in brain metastases from lung and breast cancer
The US Food and Drug Administration (FDA) has cleared T-Maximum to initiate a phase 2 clinical study of MT027, its internally-developed, B7-H3-targeted universal (allogeneic)...
Eli Lilly’s Jaypirca (pirtobrutinib) receives expanded indication from US FDA for certain patients with previously untreated CLL/SLL
The US Food and Drug Administration (FDA) has approved an additional indication for Eli Lilly and Company’s Jaypirca (pirtobrutinib, 100 mg & 50 mg tablets),...
CSL and Alentis announce global partnership to develop and commercialise lixudebart for rare kidney and liver diseases
CSL and Alentis Therapeutics have entered into an exclusive global collaboration agreement to co-develop and co-promote lixudebart, which has the potential to become a...
HanchorBio announces US FDA clearance of IND application for HCB303, a next-generation trispecific immunotherapy
The US Food and Drug Administration (FDA) has cleared the investigational new drug (IND) application for HCB303 developed by HanchorBio, a global clinical-stage biotechnology...
Lundbeck presents phase 1b data for Lu AF28996 in advanced Parkinson’s disease, as phase 2 trial begins
H Lundbeck has announced results from an open-label phase 1b trial evaluating Lu AF28996, a novel, investigational, oral prodrug of D1-like/D2-like dopamine receptor agonist,...
Beactica Therapeutics selects BEA-28 as a preclinical candidate and first-in-class TEAD degrader for biomarker-selected cancers
Beactica Therapeutics AB, a Swedish precision medicine company, has selected BEA-28 as a preclinical candidate for its TEAD programme, which is aimed at developing...
Carbogen Amcis announces successful first FDA pre-approval inspection at its Vionnaz site
Carbogen Amcis, a leading pharmaceutical process development and active pharmaceutical ingredient (API) manufacturing company, announces the successful completion of the first US Food and Drug...
Thermo Fisher Scientific showcases new solutions and expanded capabilities to accelerate drug development at CPHI Milan 2026
Thermo Fisher Scientific, a world leader in serving science, is expanding its drug development, manufacturing and clinical capabilities to help pharmaceutical and biotechnology companies...
Clinical Trials Insights
Vasa Therapeutics announces positive topline results from randomised, placebo-controlled phase 1c trial of VS-041 for treatment of heart failure with preserved ejection fraction (HFpEF)
Vasa Therapeutics has announced positive results from a randomised, placebo-controlled phase 1c trial of its lead investigational therapy, VS-041, a narrow spectrum small molecule...
Orphalan expands global phase 3 study in Wilson disease to China marking first patient randomised worldwide
Orphalan SA today announced the expansion of the study into China, marking the formal randomisation of the first participant into the study globally. The...
Rapport Therapeutics announces positive topline results from its phase 2 trial of RAP-219 for the treatment of bipolar mania
Rapport Therapeutics, a clinical-stage biotechnology company dedicated to the discovery and development of small molecule precision medicines for patients with neurological and psychiatric disorders,...
Dr Elizabeth Rohrs of the Royal Columbian Hospital reports a 39% reduction in ICU pneumonia rates among patients treated with nasal photodisinfection at ESICM
Dr Elizabeth Rohrs PhD, RRT, principal investigator at Royal Columbian Hospital (RCH) and RCH Foundation Research Director, recently presented findings from the SMURF (Suppression...
Muna Therapeutics announces positive phase 1 results supporting potential of oral small-molecule TREM2 modulator, MNA-001, in Alzheimer’s disease
Muna Therapeutics (Muna), a clinical-stage biotechnology company developing innovative treatments for neurodegenerative diseases, has announced positive results from its phase 1 study of MNA-001,...
VIDEOS
Pharma in Healthcare
CPHI Milan pharma award winners receive recognition
Every year on the first day of the worldwide show – CPHI Milan – runs the CPHI Celebration, where winners of the CPHI Pharma...
Abbott receives FDA approval for new CardioMEMS HF system capabilities that help patients engage in the care of their heart condition
The US Food and Drug Administration (FDA) has approved for Abbott’s updates to the CardioMEMS HF System that enable new patient-facing capabilities through the...
American Regent issues voluntary nationwide recall of three lots of epinephrine injection, due to the presence of particulate matter and lack of assurance of...
American Regent is conducting a nationwide voluntary recall of three lots of epinephrine injection, USP 30 mg/30 mL (1 mg/mL) multi dose vials to the...
Roche expands cyclospora testing portfolio to support US public health response
As a cyclospora outbreak continues to spread throughout the United States, Roche, in collaboration with subsidiary TIB MOLBIOL, has made available two new flexible and...
Sanofi’s MenQuadfi approved in the EU for use in infants from age six weeks against invasive meningococcal disease
The European Commission (EC) has approved an extension of the indication for Sanofi’s MenQuadfi (meningococcal Group A, C, W and Y conjugate vaccine) to...
Technology and Automation
Merck to outsource CDMO business to specialist Lonza
Merck, a leading science and technology company, has signed a definitive agreement to divest its contract development and manufacturing organization (CDMO) business within its...
Abbott receives FDA approval for new CardioMEMS HF system capabilities that help patients engage in the care of their heart condition
The US Food and Drug Administration (FDA) has approved for Abbott’s updates to the CardioMEMS HF System that enable new patient-facing capabilities through the...
Hovione to commission world’s first ConsiGma CDC flex, bringing next-generation continuous tableting to the US
Hovione, a globally integrated pharmaceutical contract development and manufacturing organisation (CDMO), will commission the world's first ConsiGma CDC flex – a next generation continuous...
Brainomix and Endeavor present positive results from quantitative image analysis of phase2a idiopathic pulmonary fibrosis (IPF) trial
Brainomix, a leading medtech company specialising in AI-powered imaging tools for lung disease and stroke; and Endeavor BioMedicines, a clinical-stage biotechnology company, presented positive...
Bio-Rad launches PTC Harmony 96 and PTC Harmony Deepwell thermal cyclers
Bio-Rad Laboratories has launched the PTC Harmony Thermal Cycler line, designed to offer broader access to optimised workflows for PCR applications such as sequencing,...
Drug delivery and supply chain
PacBio and Verily Health announce multi-year strategic collaboration to scale long-read genomics for biomedical AI
PacBio, a developer of advanced sequencing technologies, and Verily Health, a healthcare data intelligence company, have announced a multi-year strategic collaboration to integrate PacBio HiFi...
ScionxBio announces collaboration to develop long-acting xRNA therapeutics
ScionxBio has entered into a worldwide strategic collaboration and licensing agreement with Sanofi to develop and commercialise extended exposure versions of certain Sanofi mRNA...
Armenia grants first marketing authorisations for Agenus’ BOT+BAL in previously treated MSS metastatic colorectal cancer
The Ministry of Health of the Republic of Armenia has granted marketing authorisations for Agenus’ Botvymo (botensilimab, BOT) and Evamplix (balstilimab, BAL), each approved for use...
Sterling expands ADC manufacturing capacity and capabilities
Contract development and manufacturing organisation (CDMO), Sterling Pharma Solutions has announced completion of an additional, large-scale GMP manufacturing suite at its dedicated bioconjugation facility...
Merck to outsource CDMO business to specialist Lonza
Merck, a leading science and technology company, has signed a definitive agreement to divest its contract development and manufacturing organization (CDMO) business within its...
Conferences and events
UAE investment drives Middle East biopharma transformation as precision medicine set for double-digit growth
The UAE is laying the foundations for the Middle East’s next phase of biopharma growth, with national investment in genomics, artificial intelligence (AI) and...
Plan now to visit World Health Expo (WHX) in Dubai 2027 25–28 January 2027, Dubai Exhibition Centre (DEC), Expo City and Dubai World Trade...
World Health Expo (WHX) 2027 is a leading B2B healthcare event bringing together healthcare professionals, decision-makers, innovators and organisations from across the global healthcare...
Omega-3 EPA linked to longer survival after surgery for colorectal cancer liver metastases
Patients assigned to receive high-dose eicosapentaenoic acid (EPA), an omega-3 fatty acid, before and after surgery for colorectal cancer liver metastases had longer overall...
Machine learning could help identify people at higher risk of common cancers using routine health data
Machine learning models using routinely collected health information, such as blood tests, medical history and lifestyle factors, could help identify people at higher risk...
CPHI Milan pharma award winners receive recognition
Every year on the first day of the worldwide show – CPHI Milan – runs the CPHI Celebration, where winners of the CPHI Pharma...
Finance, mergers and appointments
PAI Pharma acquires Nexus Pharmaceuticals, expanding portfolio of sterile injectable products
PAI Pharma, has acquired Nexus Pharmaceuticals, a pharmaceutical company specialising in the development and commercialisation of injectable medicines used in critical care, oncology, and...
Lilly breaks ground in Pennsylvania’s Lehigh Valley on a $3.5 billion site
Eli Lilly and Company has commenced building a $3.5 billion manufacturing facility in Pennsylvania's Lehigh Valley.
The site is one of 10 new US manufacturing...
Bolt Biotherapeutics announces acquisition of Prana Therapies and US$120 million concurrent private placement to advance PRA-216 in multiple high-value inflammatory indications
Bolt Biotherapeutics has acquired Prana Therapies, a clinical-stage biotechnology company pioneering next-generation half-life-extended multi-specific antibodies designed to deliver best-in-disease therapies
Following the acquisition, the company...
P95 Julius Clinical becomes Akeura, a specialist CRO in clinical development and real-world evidence
P95 Julius Clinical has become Akeura, a global specialist contract research organisation (CRO) with dual expertise in clinical and real-world settings. The launch of...
Adalvo expands biosimilars portfolio through acquisition of romiplostim biosimilar programme from Enzene
Adalvo has acquired the romiplostim biosimilar programme referencing Nplate from Enzene, strengthening its biosimilars portfolio and accelerating the company’s expansion into complex biological medicines.
The...
- Advertisement -
- Advertisement -
MOST POPULAR POSTS
© 2026 Pharma Press Global.

